UK markets closed

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.4700+0.0700 (+1.59%)
At close: 04:00PM EDT
4.5300 +0.06 (+1.34%)
After hours: 04:07PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.4000
Open4.4500
Bid4.4700 x 1000
Ask4.5000 x 500
Day's range4.3800 - 4.5300
52-week range3.1700 - 5.7500
Volume2,143,613
Avg. volume2,933,090
Market cap1.21B
Beta (5Y monthly)1.32
PE ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings date08 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.08
  • GlobeNewswire

    MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation of Clofazimine Inhalation Suspension (MNKD-101) for the treatment of nontuberculous mycobacterial (NTM) lung disease.

  • GlobeNewswire

    MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 8, 2024. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentat

  • GlobeNewswire

    MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

    First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteersEnrollment of first study participant anticipated in June 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will proceed with a first-i